0950 (0950) Fair Value & Analysis

Healthcare · Market cap HK$612M

0 0950 0950 · HK

PriceHK$1.03

Fair ValueHK$2.65

Upside+157.3%

Quality43/100

Evidence: Medium Range HK$2.19 – HK$3.32

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −2.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.03 – HK$2.54 · fair‑value band HK$2.19 – HK$3.32 · the HK$1.03 price screens below the HK$2.65 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0950 (0950) currently trades at HK$1.03, while our model-based Fair Value estimate is HK$2.65 — implying the stock looks roughly 157.3% undervalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 0950 generated revenue of HK$1.4B at a net margin of 6.4%. Revenue declined 0.1% year over year. It earns a return on equity of 2.9%. The balance sheet holds a net cash position of HK$39.6M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.4B

Revenue growth (YoY) -0.1%

Net margin 6.4%

Return on equity 2.9%

Free cash flow HK$101M FY2025

P/E ratio 6.5

More key figures

Operating margin 5.9%

EPS (TTM) HK$0.1100

Dividend yield 4.4%

EPS growth (YoY) -19.2%

Net cash HK$39.6M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0950 reported revenue of HK$1.4B in FY2025 versus HK$1.3B in FY2021, a compound +3.2%/yr. Reported net income was HK$91.9M in FY2025, compounding −53.6%/yr from FY2021.

Revenue +3.2%/yr

FY21 HK$1.3B

FY22 HK$1.2B

FY23 HK$1.1B

FY24 HK$1.4B

FY25 HK$1.4B

Net income −53.6%/yr

FY21 HK$2.0B

FY22 HK$51.3M

FY23 HK$16.7M

FY24 HK$93.1M

FY25 HK$91.9M

Is 0950 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0950 (0950) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$2.65 versus a price of HK$1.03 — about +157% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0950?

Our model-based fair value for 0950 is HK$2.65 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.03.

What is the quality score of 0950?

0950 has a Quality Score of 43/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0950 (0950)?

0950 reported trailing-twelve-month revenue of about HK$1.4B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0950?

The net profit margin of 0950 is about 6.4%, meaning it keeps roughly 6.4% of revenue as net income. Based on the latest reported figures.

Does 0950 pay a dividend?

0950 currently shows a dividend yield of about 4.37% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.